Targeting MAPK Signalling Pathways to Stop GBM Tumor Cell Proliferation
Time: 12:00 pm
day: Conference Day 2
Details:
- Introducing a new generation of brain penetrant BRAF inhibitors for GBM
- ABM-1310 for BRAF v600-mutant GBM tumors- Phase I study
- Clinical evidence of ABM-1310 in high grade gliomas including GBM
